1.The Test of Xuejiejiawei Granule Acute Toxicity The Largest Dose (MTD) of the Determination
Journal of Zhejiang Chinese Medical University 2006;0(05):-
[Objective]Modify Xuejiejiawei Granule judgment toxic particles to guide its clinical drug safety.[Method]Make different dosages,give the mouse to fill stomach,from the observing mouse's physiological condition to judging the medicine toxic.[Result]36 mice after given the medicine observation period do not have an example to die,after the dissection the internal organs have non-pathological changes.[Conclusion] Looking at Xuejiejiawei Granule from the medicine toxic effect,the Xuejie adding the taste pellet is a safe medicine.
2.Applications of nanometer zinc oxide in biomedicine
International Journal of Biomedical Engineering 2015;38(5):306-309,318
Nanometer zinc oxide (Nano-ZnO) has been widely applied in many fields such as rubber,ceramics,textile,cosmetics,etc.due to its excellent physical,chemical and biological properties.In recent years,its applications in biomedicine have been paid more and more attention.This paper introduces the unique optical,chemical,mechanical,semi-conducting and biological properties of Nano-ZnO.Meanwhile,the applications of Nano-ZnO in bio-sensing and detection,biological nutrition,medical treatment,biological imaging,drug delivery,tumor cells targeted killing and translational medicine are also reviewed,and the brief outlook on the applications is presented.
3.Free-sugar suspension granule of compound Saliva Miltiorrhiza
Chinese Traditional Patent Medicine 1992;0(12):-
AIM: To select the proper excipients for granule of compound Saliva Miltiorrhiza and the preparative process. METHODS: Building up properties, solubility and resistance to humid were used as the judgement criteria, the kinds and ratio of the excipients and preparative process sieved out. RESULTS: Properere excipent combination consisted of one portion of the extract of compound Salvia Miltiorrhiza, 1.6 times dextin, 2.6% CMC Na, 1% PVP, 2.6% CMS Na. CONCLUSION: The process and its excipent combination is better than the other process of formulation.
4. Comparison of the influnce of gefitinib treatment on quality of life between non-small cell lung cancer patients with high and low ECOG-PS score
Tumor 2013;33(4):339-344
Objective: To explore the quality of life and drug toxicity in NSCLC (non-small cell lung cancer) patients who have a ECOC (Eastern Cooperative Oncology Group)-PS (performance status) score ≥3 and a response to gefitinib more than 6 months, and to explore the possibily of gefitinib applying in NSCLC patients with a ECOG-PS score ≥3. Methods: NSCLC patients histologically and (or) cytologically confirmed were divided into trial group (ECOG-PS score ≥3) and control group (ECOG-PS score ≤2). The patients in the two groups were treated with a dose of 250 mg/d gefitinib. The efficacy, change of quality of life and the toxicity were evaluated. Results: Eighty-eight NSCLC patients were enrolled in this study (trial group: n = 27; control group: n = 61). The median follow-up time was 20.0 months. All patients in the two groups could be évaluable. In the trial group, 4 (14.81%) patients obtained CR (complete response), 20 (74.07%) patients obtained PR (partial response), 3 (11.11%) patients obtained SD (stable disease); the response rate was 88.89% (24/27). In the control group, 10 (16.39%) patients obtained CR (complete response), 43 (70.49%) patients obtained PR (partial response), 8 (13.11%) patients obtained SD (stable disease); the response rate was 86.89% (53/61). There was no difference in response rate between the two groups (P = 0.794). The median time to symptom improvement of the trial group and the control group were 10.0 and 14.0 d, respectively (P = 0.073), the median PFS (progression-free survival) were 8.0 and 7.0 momths, respectively (P = 0.421). The 1-, 2- and 3-year survival rates were 59.269% (16/27), 25.93% (7/27) and 3.70% (1/27) in the trial group and 57.38% (35/61), 21.31% (13/61) and 6.56% (4/61), respectively. There was no difference in survival rate between the two groups (P = 0.180). The ECOG-PS score after gefitinib therapy (vs before gefitinib therapy) was significantly decreased in the two groups (Trial group Z = -4.062, P = 0.000; Control group Z = -4.031, P = 0.000), and the percent decrease of ECOG-PS score after gefitinib therapy in the trial group was significantly higher as compared with that in the control group. The toxicities of gefitinib therapy were tolerated. Conclusion: Gefitinib can be safely applied in NSCLC patients with ECOG-PS score ≥3. There is no difference in survival time between NSCLC patients with ECOG-PS score ≥3 and ≤2, but the quality of life in NSCLC patients with ECOG-PS score 2= 3 is significantly impoved as compard with NSCLC patients with ECOG-PS score ≤2 after gefitinib therapy. Copyright © 2013 by TUMOR.
6.Effects of lipopolysaccharide on proliferating cell nuclear antigen expression on alveolar macrophages and Fas/FasL system expression on alveolar type Ⅱ epithelial cells in smoking rats
Juan FU ; Yongjian XU ; Zhenxiang ZHANG
Chinese Journal of Pathophysiology 1986;0(02):-
AIM: To study the effect of proliferating cell nuclear antigen (PCNA) expression on alveolar macrophages (AM) and Fas/FasL expression on alveolar type Ⅱ epithelial cells induced by lipopolysaccharide (LPS) in smoking rats. METHODS: Immunohistochemistry SABC and immunofluorescence techniques were used to examine PCNA expression on AM and Fas/FasL system expression on alveolar type Ⅱ epithelial cells in smoking rats of different stages induced by LPS. RESULTS: The AM PCNA expression in smoking rats reached the highest level after 3 or 4 months. The AM PCNA expression in every groups stimulated by LPS significantly increased ( P
7.The clinical implications of changes in peripheral blood follicle stimulating hormone (FSH) and luteinizing hormone (LH) in early stage of trauma
Gang WU ; Zanzhi WANG ; Juan FU
Medical Journal of Chinese People's Liberation Army 2001;0(11):-
25) and in the group with complication of craniocerebral injury (P25) were significantly increased compared with other groups (P5) showed significunt difference as compared with that of with other groups (P
8.The efficacy of folic acid combined with mecobalamine for the treatment of mild cognitive impairment in patients with cerebral small vessel disease and hyperhomocysteinemia
Zhaohui FU ; Juan WU ; Dengrong CHEN
Chongqing Medicine 2014;(9):1055-1057
Objective To observe the efficacy of folic acid combined with mecobalamine for the treatment of vascular mild cogni-tive impairment (VMCI) in patients with cerebral small vessel disease (SVD) and hyperhomocysteinemia(Hcy) .Methods A total of 84 VMCI patients with cerebral small vessel disease and Hcy were randomly divided into combination group and control group . Two groups received conventional therapy for 6 months .Besides ,the combination group received folic acid combined with mecobal-amin .The level of plasma Hcy and ADAS-cog score were observed before and after 3 months and 6 months treatment .Results Af-ter treatment ,plasma Hcy significantly lower in the combination group (P<0 .01) ,whereas it did not show any improvement in the control group .ADAS-cog scores in combination group decreased compared with that of before treatment ,but there was no statisti-cally significant difference after 3 months treatment(P>0 .05) .However ,after 6 months treatment ,the ADAS-cog scores decreased obviously than that in the before treatment group (P<0 .05) .ADAS-cog scores in control group increased compared with before treatment ,but there was no statistically significant difference in after treatment (P>0 .05) .After 3 months treatment ,there was no significant difference on ADAS-cog score between combination group and control group (P>0 .05) ,however ,there had significant difference between the two groups after 6 months treatment(P<0 .05) .Conclusion The level of plasma Hcy could be reduced by adding folic acid and mecobalamin .Treatment of hyperhomocysteinemia may delay the progression of vascular cognitive impairment w hich caused by cerebral small vessel disease .
9.Extraction and Isolation of the Protein Groups with Anti-tumor Activity from Pinellia Ternata Rhizhome
Yun FU ; Bisheng HUANG ; Juan LI
Chinese Journal of Information on Traditional Chinese Medicine 2006;0(01):-
Objective To isolate the anti-tumor protein groups from Pinellia ternata rhizome and investigate the anti-tumor activity of these protein groups on Bel-7402 cell. Methods The total raw protein was isolated with sepharose column chromatography. Methyl-thiazolyl-tetrazolinm (MTT) was used to analyze the effect of Pinellia ternata Protein on inhibiting growth of tumor cells. Apoptosis was detected by flow cytometry (FCM). Results The 30% and 60% (NH4)2SO4 deposition part of total proteins from Pinellia ternata rhizome have no certain relationship between quantity and inhibitory action, but protein peak 3 eluted with 0.05 mol/L or 0.1 mol/L NaCl from 30% (NH4)2SO4 deposition part showed a effect of concentration depending. FCM analysis showed that the protein of 30% (NH4)2SO4 deposition part could induce apoptosis. Conclusion The 30% (NH4)2SO4 deposition part of total proteins from Pinellia ternata rhizome could significantly inhibit Bel-7402 growth and induce its apoptosis.
10.Epidemic situation of acute schistosomiasis in Jingzhou City, 2004 -2008
Zhengyin FU ; Juan DONG ; Meizhi YUAN
Chinese Journal of Schistosomiasis Control 2009;21(6):490,495-
The data of 162 cases with acute schistosomiasis in Jingzhou City from 2004 to 2008 was analyzed, and the resultsshowed that the endemic situation of acute schistosomiasis decreased year by year, and the children aged 5-14 years were themain infection population, and swimming and playing in water was the main infection mode. It is suggested that health educationfor residents especially students should be strengthened to improve their conscious for disease prevention.